Antileishmanial Effects of Synthetic EhPIb Analogs Derived from the Entamoeba histolytica Lipopeptidephosphoglycan

With an estimated number of new cases annually of approximately 1.4 million, leishmaniasis belongs to the most important parasitic diseases in the world. Nevertheless, existing drugs against leishmaniasis in general have several drawbacks that urgently necessitate new drug development. A glycolipid...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Antimicrob Agents Chemother
Главные авторы: Fehling, Helena, Choy, Siew Ling, Ting, Frederic, Landschulze, Dirk, Bernin, Hannah, Lender, Sarah Corinna, Mühlenpfordt, Melina, Bifeld, Eugenia, Eick, Julia, Marggraff, Claudia, Kottmayr, Nadine, Groneberg, Marie, Hoenow, Stefan, Sellau, Julie, Clos, Joachim, Meier, Chris, Lotter, Hannelore
Формат: Artigo
Язык:Inglês
Опубликовано: American Society for Microbiology 2020
Предметы:
Experimental Therapeutics
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7318009/
https://ncbi.nlm.nih.gov/pubmed/32393489
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00161-20
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы